背景:三调蛋白(人多价免疫球蛋白[Ig]M〜23%,IgA~21%,IgG〜56%制剂)先前已与有创机械通气(IMV)的严重社区获得性肺炎患者亚群的较低死亡率相关,并且有明显的炎症迹象。ESsCOVID试验的假设是,三调节蛋白可以预防炎症驱动的严重冠状病毒疾病2019(COVID-19)进展为危重疾病甚至死亡。
方法:将患有严重COVID-19的成年人随机分组,除标准治疗外,连续5天接受静脉输注三调节素或安慰剂。主要疗效终点是临床恶化(第6-29天)和28天全因死亡率(第1-29天)的复合。
结果:一百六十六名患者接受了三调节蛋白(n=84)或安慰剂(n=82)。33名患者死亡,9在治疗阶段。总的来说,84.9%和76.5%的患者完成治疗和随访,分别。主要疗效终点报告33.3%的患者接受三调蛋白治疗,34.1%的患者接受安慰剂治疗(P=0.912)。在有创机械通气第29天康复的患者比例没有观察到差异。或无重症监护病房的日子。因治疗引起的不良事件发生率相当。对早期全身性炎症患者进行事后分析,排除基线时CRP高(>150mg/L)和/或D-二聚体(≥3mg/L)和/或血小板计数低(<130×109/L)的患者。三调节蛋白组中的47名患者和安慰剂组中的49名患者符合这些标准。观察到临床恶化和死亡率的差异为15.5个百分点,有利于三调蛋白(95%置信区间:-4.46,34.78;P=0.096)。
结论:尽管总体人群的主要结局没有差异,对早期全身性炎症患者亚组的观察表明,三调节蛋白在这种情况下可能具有潜力,值得进一步研究.Esscovid是在诊所进行登记的。2020年10月6日政府。:NCT04576728。
BACKGROUND: Trimodulin (human polyvalent immunoglobulin [Ig] M ~ 23%, IgA ~ 21%, IgG ~ 56% preparation) has previously been associated with a lower mortality rate in a subpopulation of patients with severe community-acquired pneumonia on invasive mechanical ventilation (IMV) and with clear signs of inflammation. The hypothesis for the ESsCOVID trial was that trimodulin may prevent inflammation-driven progression of severe coronavirus disease 2019 (COVID-19) to critical disease or even death.
METHODS: Adults with severe COVID-19 were randomised to receive intravenous infusions of trimodulin or placebo for 5 consecutive days in addition to standard of care. The primary efficacy endpoint was a composite of clinical deterioration (Days 6-29) and 28-day all-cause mortality (Days 1-29).
RESULTS: One-hundred-and-sixty-six patients received trimodulin (n = 84) or placebo (n = 82). Thirty-three patients died, nine during the treatment phase. Overall, 84.9% and 76.5% of patients completed treatment and follow-up, respectively. The primary efficacy endpoint was reported in 33.3% of patients on trimodulin and 34.1% of patients on placebo (P = 0.912). No differences were observed in the proportion of patients recovered on Day 29, days of invasive mechanical ventilation, or intensive care unit-free days. Rates of treatment-emergent adverse events were comparable. A post hoc analysis was conducted in patients with early systemic inflammation by excluding those with high CRP (> 150 mg/L) and/or D-dimer (≥ 3 mg/L) and/or low platelet counts (< 130 × 109/L) at baseline. Forty-seven patients in the trimodulin group and 49 in the placebo group met these criteria. A difference of 15.5 percentage points in clinical deterioration and mortality was observed in favour of trimodulin (95% confidence interval: -4.46, 34.78; P = 0.096).
CONCLUSIONS: Although there was no difference in the primary outcome in the overall population, observations in a subgroup of patients with early systemic inflammation suggest that trimodulin may have potential in this setting that warrants further investigation. ESSCOVID WAS REGISTERED PROSPECTIVELY AT CLINICALTRIALS.GOV ON OCTOBER 6, 2020.: NCT04576728.